IV = Intravenous, SC = Subcutaneous
Tecentriq® Healthcare Provider Letters:
Mechanism of Action
Tecentriq® Mechanism of Action
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT
Learn more about Tecentriq Hybreza™
Tecentriq Hybreza Dosing
Dosing Information
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT
Publications and Congresses
The information in this section may include content beyond what is in the FDA-approved label. Because the FDA has not approved such content, no conclusions regarding safety or efficacy may be made. Providing this information should not be construed as recommendation for use of a Genentech product for unapproved uses. For FDA-approved products please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product(s) for its approved indication(s).
Publications: The list of publications is not an exhaustive list of published materials on the product. The list of references by data topics is selected per evidence-based medicine criteria. To browse a full listing of published scientific literature:
Congresses: The list of congresses is a subset of Roche/Genentech posters and oral presentations for the product with data presented at scientific meetings in the recent 24 months. To browse full Roche/Genentech congress presentations and posters:
Showing 64 out of 64 results
-
20240731 IMbrave150: efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with barcelona clinic liver cancer stage b unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study
Masatoshi Kudo, Richard S. Finn, Peter R. Galle, et al. Liver Cancer. 2022 Nov 28;12(3):238-250.Hepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20240731 Atezolizumab for advanced alveolar soft part sarcoma
Alice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, et al. N Engl J Med. 2023 Sep 7;389(10):911-921.Alveolar Soft Part Sarcoma (ASPS)Pivotal Trial(s)Intravenous -
20240731 Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma: results from older adults enrolled in the IMbrave150 randomized clinical trial
Li D, Toh HC, Merle P, et al. Liver Cancer. 2022 Jul 13;11(6):558-571.Hepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20240731 Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: results from the IMbrave150 trial
Riad Salem, Daneng Li, Nicolas Sommer, et al. Cancer Med. 2021 Aug;10(16):5437-5447.Hepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20240731 Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
Peter R. Galle, Richard S. Finn, Shukui Qin, et al. Lancet Oncol. 2021 Jul;22(7):991-1001.Hepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20240731 IMbrave150: exploratory analyses for investigating associations between overall survival and depth of response or duration of response in patients with unresectable hepatocellular carcinoma (HCC)
Kudo M, Yamashita T, Finn R S, et al. Presented at the European Society of Medical Oncology Asia. Singapore, Republic of Singapore. December 1-3, 2023.Hepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20240621 Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in IMbrave150
Richard S. Finn, Peter R. Galle, Michel Ducreux, et al. Liver Cancer. 2024 June; 1-14.Hepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20240603 IMpower010: Disease-Free Survival Final Analysis and Second Overall Survival Interim Analysis Results After ≥5 years of Follow-up of a Phase III Study of Adjuvant Atezolizumab vs Best Supportive Care in Resected Stage IB-IIIA Non-Small Cell Lung Cancer
Wakelee HA, Altorki N, Zhou C, et al. Presented at the American Society of Clinical Oncology (ASCO); May 31-June 4, 2024; Chicago, IL, USAAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Pivotal Trial(s)Intravenous -
20240509 Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC
Burotto M, Zvirbule A, Alvarez R, et al. J Thorac Oncol. 2024 May 9:S1556-0864(24)00210-7Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Alveolar Soft Part Sarcoma (ASPS)Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Hepatocellular Carcinoma (HCC)MelanomaMetastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)IntravenousSubcutaneous -
20240321 Primary results from IMscin002: A study to evaluate patient-and healthcare professional-reported preferences for atezolizumab subcutaneous vs intravenous for the treatment of non-small cell lung cancer
Cappuzzo F, Zvirbule Z, Korbenfeld E, et al. Presented at European Lung Cancer Congress 2024. Prague, Czech Republic. March 20-23, 2024.Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Alveolar Soft Part Sarcoma (ASPS)Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Hepatocellular Carcinoma (HCC)MelanomaMetastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)IntravenousSubcutaneous -
20231023 IMpower010: exploratory analysis of disease-free survival by TGFβ cancer-associated fibroblast gene signature expression in patients with resected NSCLC treated with atezolizumab or best supportive care
Altorki N, Reck M, Wakelee H, et al. Presented at the European Society of Medical Oncology. Madrid, Spain. October 20-24, 2023.Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20231023 IMscin001 Part 2 updated results: Efficacy, safety, immunogenicity, healthcare provider perspectives and patient-reported outcomes from the randomised Phase III study of atezolizumab subcutaneous vs intravenous in patients with locally advanced or metastatic non-small-cell lung cancer
Burotto M, Zvirbule A, Alvarez R, et al. Presented at the European Society of Medical Oncology. Madrid, Spain. October 20-24, 2023.Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Alveolar Soft Part Sarcoma (ASPS)Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Hepatocellular Carcinoma (HCC)MelanomaMetastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)IntravenousSubcutaneous -
20231021 IMreal Cohort 4: third interim analysis of efficacy and safety in patients with extensive-stage small cell lung cancer receiving atezolizumab plus carboplatin and etoposide as first-line therapy under real-world conditions
Popat S, Girard N, Shoshkova S, et al. Presented at the European Society of Medical Oncology. Madrid, Spain. October 20-24, 2023.Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Real World Experience (RWE)Intravenous -
20230911 IMpower010: exploratory analysis of tumour mutational burden and disease-free survival with adjuvant atezolizumab in NSCLC
Felip E, Srivastava M, Reck M, et al. Presented at the World Conference on Lung Cancer. Singapore. September 9-12, 2023Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20230910 Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: IMbrella A extension study results
Liu S, Dziadziuszko, R, Sugawara S, et al. Presented at the World Conference on Lung Cancer. Singapore. September 9-12, 2023Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Supportive StudiesIntravenous -
20230717 Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
Felip E, Altorki N, Zhou C, et al. Ann Oncol. 2023 Oct;34(10):907-919.Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Pivotal Trial(s)Intravenous -
20230604 IMpower010: exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care
Reck M, Srivastava M, Wakelee H, et al. Presented at the American Society of Clinical Oncology Annual Meeting. Chicago, IL. June 2-6, 2023Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20230601 IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
Burotto M, Zvirbule Z, Mochalova A, et al. Ann Oncol. 2023 Aug;34(8):693-702Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Alveolar Soft Part Sarcoma (ASPS)Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Hepatocellular Carcinoma (HCC)MelanomaMetastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)IntravenousSubcutaneous -
20230601 Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small cell lung cancer
Das M, Ogale S, Jovanoski N, et al. Immunotherapy. 2023 Jun;15(8):573-581.Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Health Economics and Outcomes Research (HEOR)Intravenous -
20230322 Budget impact of maintaining atezolizumab as a preferred treatment option for adjuvant treatment of patients with early non-small cell lung cancer (eNSCLC)
Lee J, Maignan K, Cobden D. et al. Presented at The Academy of Managed Care Pharmacy (AMCP); March 22, 2023; San Antonio, Texas, USAAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Health Economics and Outcomes Research (HEOR)Intravenous -
20230225 Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage Non-Small Cell Lung Cancer
Lee J, Wang R, Johnson A, et al. JTO Clin Res Rep. 2023 Feb 25;4(4):100487Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Real World Experience (RWE)Intravenous -
20230120 IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study.
Kudo M, Tsuchiya K, Shao Y, et al. Presented at The ASCO Gastrointestinal Cancers Symposium (ASCO GI); January 20, 2023; San Francisco, CA, USAHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20230101 Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA.
Lee J, Wang R, Johnson A, et al. Future Oncol. 2023 Jan;19(1):37-47.Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Real World Experience (RWE)Intravenous -
20230101 Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Ascierto P, Stroyakovskiy D, Gogas H, et al. Lancet Oncol. 2023 Jan;24(1):33-44.MelanomaPivotal Trial(s)Intravenous -
20221208 IMscin001 (Part 2: Randomized Phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Burotto M, Zvirbule Z, Mochalova A, et al. Presented at ESMO Immuno-Oncology. Geneva, Switzerland. December 7-9, 2022.Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Alveolar Soft Part Sarcoma (ASPS)Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Hepatocellular Carcinoma (HCC)MelanomaMetastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)IntravenousSubcutaneous -
20221208 IMpower010: Exploratory overall survival with adjuvant atezolizumab vs best supportive care in stage II-IIIA NSCLC with high PD-L1 expression
Rittmeyer A, Felip E, Altorki N, et al. Presented at The ESMO Iummuno Oncology Congress (ESMO IO); December 8, 2022; Geneva, SwitzerlandAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20221207 IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
Felip E, Srivastava M, Reck M, et al. Presented at The ESMO Immuno Oncology Congress (ESMO IO); December 7, 2022; Geneva, SwitzerlandAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20221112 IMbrave150: exploratory efficacy and safety of atezolizumab + bevacizumab vs sorafenib in patients with hepatocellular carcinoma (HCC) with non-viral etiology in a global phase III study
Zhu A.X., Finn R.S., Ducreux M, et al. Presented at The American Association for the Study of Liver Diseases (AASLD); November 12, 2021; Virtual ConferenceHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20221001 Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
D'Alessio A, Fulgenzi C, Nishida N, et al. Hepatology. 2022 Oct;76(4):1000-1012.Hepatocellular Carcinoma (HCC)Real World Experience (RWE)Intravenous -
20220901 Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice
Tanaka T, Hiraoka A, Tada T, et al. Hepatol Res. 2022 Sep;52(9):773-783.Hepatocellular Carcinoma (HCC)Real World Experience (RWE)Intravenous -
20220808 IMpower010: overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC
Felip E, Altroki N, Vallieres, et al. Presented at The International Association For the Study of Lung Cancer (IASLC); August 8 2022; Vienna, AustriaAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20220401 Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Cheng A, Qin S, Ikeda M, et al. J Hepatol. 2022 Apr;76(4):862-873.Hepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20220331 Atezolizumab vs best supportive care in Stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal Phase III IMpower010 study
Felip E, Altroki N, Zhou C, et al. Presented at The European Lung Cancer Congress (ELCC); March 31, 2022; Virtual ConferenceAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20220328 Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers
Himmelsbach V, Pinter M, Scheiner B, et al. Cancers (Basel). 2022 Mar 28;14(7):1722.Hepatocellular Carcinoma (HCC)Real World Experience (RWE)Intravenous -
20220122 IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study.
Toh H, Galle P, Zhu A, et al. Presented at The ASCO Gastrointestinal Cancers Symposium (ASCO GI) ; January 22, 2022; San Francisco, CA, USAHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20211209 IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
Zhou C, Thakur M, Srivastava M, et al. Presented at ESMO Immuno Oncology Congress (ESMO IO); December 9, 2021; Virtual ConferenceAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20211009 Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E, Altorki N, Zhou C, et al. Lancet 2021 Oct 9;398(10308):1344-1357.Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Pivotal Trial(s)Intravenous -
20210920 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
Felip E, Vallieres E, Zhou C. et al. Presented at The European Society For Medical Oncology (ESMO); September 20, 2021; Virtual ConferenceAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20210916 Adoption and early clinical outcomes of atezolizumab (atezo) + carboplatin and etoposide (CE) in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the real-world (RW) setting
Tsui D.C.C, Polito L, Madhavan S. et al. Presented at The European Society For Medical Oncology (ESMO); September 16, 2021; Virtual ConferenceExtensive-Stage Small Cell Lung Cancer (ES-SCLC)Real World Experience (RWE)Intravenous -
20210916 IMbrave150: Exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) + bevacizumab (bev) or sorafenib (sor)
Kudo M, Finn R, Galle P, et al. Presented at The European Society For Medical Oncology (ESMO); September 16, 2021; Virtual ConferenceHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20210908 IMpower010: characterization of stage Ib-IIIa NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab
Altorki N, Felip E, Zhou C, et al. Presented at The World Conference on Lung Cancer (WCLC); September 8, 2021; Virtual ConferenceAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Exploratory AnalysisIntravenous -
20210815 IMbrave150: Efficacy and safety of atezolizumab plus bevacizumab vs sorafenib by baseline varices status in patients with hepatocellular carcinoma
Merle P, Ducreux M, Finn R, et al. Presented at The Asia Pacific Primary Liver Cancer Expert Meeting Conference (APPLE); August 15, 2021; Virtual ConferenceHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20210701 Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-Label IMbrave150 study
Qin S, Ren Z, Feng Y, et al. Liver Cancer. 2021 Jul;10(4):296-308Hepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20210624 IMbrave150: exploratory efficacy and safety results of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
Salem R, Galle P, Finn R, et al. Presented at The European Association for the Study of the Liver Congress (EASL); June 24, 2021; Virtual CongressHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20210606 IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)
Wakelee H, Altorki N, Zhou C, et al. Presented at Amercian Society Clinical Oncology (ASCO); June 6, 2021; Virtual ConferenceAdjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Pivotal Trial(s)Intravenous -
20210604 Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive stage small cell lung cancer (ES-SCLC)
Nadler E, Vasudevan A, Davies K, et al. Presented at The Amercian Society Clinical Oncology (ASCO); June 4, 2021; Virtual ConferenceExtensive-Stage Small Cell Lung Cancer (ES-SCLC)Real World Experience (RWE)Intravenous -
20210604 IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor)
Ducreux M, Zhu A, Cheng A, et al. Presented at The Amercian Society Clinical Oncology (ASCO); June 4, 2021; Virtual ConferenceHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20210604 IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study
Breder V, Vogel A, Merle P. et al. Presented at The Amercian Society Clinical Oncology (ASCO); June 4, 2021; Virtual ConferenceHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20210410 IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
Finn R, Qin S, Ikeda M et al, Presented at The American Association for Cancer Research Annual Meeting (AACR); April 10, 2021; Virtual ConferenceHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20210410 Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab + bevacizumab in HCC
Galle P, Finn R, Cheng A, et al. Presented at The American Association for Cancer Research Annual Meeting (AACR); April 10, 2021; Virtual ConferenceHepatocellular Carcinoma (HCC)Exploratory AnalysisIntravenous -
20210331 Results of a dose-finding phase 1b study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer
Felip E, Burotto M, Zvirbule Z, et al. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1142-1155Adjuvant Non-Small Cell Lung Cancer (Adj.NSCLC)Alveolar Soft Part Sarcoma (ASPS)Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Hepatocellular Carcinoma (HCC)MelanomaMetastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)IntravenousSubcutaneous -
20210220 Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133).
Liu S, Reck M, Mansfield A, et al. J Clin Oncol. 2021 Feb 20;39(6):619-630.Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Exploratory AnalysisIntravenous -
20210131 IMpower133: exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer
Reck M, Horn L, Mok T.S.K, et al. Presented at The World Conference on Lung Cancer (WCLC); January 31, 2021; Virtual ConferenceExtensive-Stage Small Cell Lung Cancer (ES-SCLC)Exploratory AnalysisIntravenous -
20201001 Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC
Herbst R, Giaccone G, de Marinis F, et al. N Engl J Med. 2020 Oct 1;383(14):1328-1339.Metastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)Intravenous -
20200919 IMpower133 characterisation of long term survivors treated first line with chemotherapy ± atezolizumab in extensive stage small cell lung cancer
Liu S, Horn L, Mok T.S.K et al. Presented at The European Society For Medical Oncology (ESMO); September 19, 2020; Virtual ConferenceExtensive-Stage Small Cell Lung Cancer (ES-SCLC)Exploratory AnalysisIntravenous -
20200919 IMbrave150: management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Ikeda M, Zhu A, Qin S, et al. Presented at The European Society For Medical Oncology (ESMO); September 19, 2020; Virtual ConferenceHepatocellular Carcinoma (HCC)SafetyIntravenous -
20200622 IMpower133: updated overall survival and exploratory analyses of first-line atezolizumab plus carboplatin/etoposide in extensive-stage small cell lung cancer
Horn L, Liu S, Mansfield A, et al. Presented at The American Association for Cancer Research Annual Meeting (AACR); June 22, 2020; Virtual ConferenceExtensive-Stage Small Cell Lung Cancer (ES-SCLC)Exploratory AnalysisIntravenous -
20200613 Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Gutzmer R, Stroyakovskiy D, Gogas H, et al. Lancet. 2020 Jun 13;395(10240):1835-1844.MelanomaPivotal Trial(s)Intravenous -
20200514 Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn R, Qin S, Ikeda M et al. N Engl J Med. 2020 May 14;382(20):1894-1905.Hepatocellular Carcinoma (HCC)Pivotal Trial(s)Intravenous -
20190701 Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West H, McCleod M, Hussein M, et al. Lancet Oncol. 2019 Jul;20(7):924-937.Metastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)Intravenous -
20181206 First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn L, Mansfield A, Szczęsna A, et Al. N Engl J Med. 2018 Dec 6;379(23):2220-2229.Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Pivotal Trial(s)Intravenous -
20181019 IMpower133: Primary efficacy and safety + CNS-related adverse events in a PhI/III study of first-line atezolizumab+ carboplatin + etoposide in extensive stage SCLC
Mok T.S.K, Reck M, Horn L, et al. Presented at The European Society For Medical Oncology (ESMO); October 19, 2018; Munich, GermanyExtensive-Stage Small Cell Lung Cancer (ES-SCLC)Pivotal Trial(s)Intravenous -
20180614 Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
Socinski M, Jotte R, Cappuzzo F, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301.Metastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)Intravenous -
20170121 Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer A, Barlesi F, Waterkamp D, et al. Lancet. 2017 Jan 21;389(10066):255-265.Metastatic Non-Small Cell Lung Cancer (mNSCLC)Pivotal Trial(s)Intravenous
No results
Try resetting the filters or selecting another category.
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT